Vlispxpert's Underground

[matt24d]

This is why I own VBIV. Their data has been better then Engerix.

Engerix-B does just under $1Billion/year in revenues and, as a practical matter, is the standard of care in Hepatitis B vaccination


Now look at how their drug compares to it. Their drug is better its just that simple.


During the presentation, Adam Finn, M.D., Ph.D., Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, discussed the successfully-met primary endpoint of CONSTANT – demonstration of consistency of immune response as measured by the geometric mean concentration (GMC) of hepatitis B antibodies (anti-HBs titers) across three consecutively-manufactured lots of vaccine. Additional data highlighted included:


Download Presentation

Watch Presentation

High anti-HBs titers: GMC of anti-HBs for Sci-B-Vac was more than 7.5x compared to Engerix-B after 2 vaccinations (day 168) and more than 3x after 3 vaccinations (day 196)
Rapid Onset of Seroprotection: After 2 vaccinations, Sci-B-Vac elicited a 90.4% seroprotection rate (SPR) compared to 51.6% with Engerix-B, increasing to 99.3% vs. 94.8% after the 3rd dose
Safety: No new or unexpected safety signals seen with either study vaccine.



Per their last Q.

Q4 2020: Submission of applications for regulatory approvals in the U.S., Europe, and Canada expected to begin.


Things are just getting interesting. Been holding a core position since .83 or so. I have bought and sold along the way but still very much feel this stock is cheap. SCI-B-VAC had better results. Even if they get 10% of the market from Engenrix that is still 100 million a year. They have a nice little cancer drug on their hands. And they just got a huge chunk of their COVID 19 drug funded. I like my chances on this one.